- Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
- Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
- Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
- Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
- Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
- Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
- Genelux Corporation Announces New Chief Financial Officer
- Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
More ▼
Key statistics
As of last trade, Genelux Corp (GNLX:NAQ) traded at 2.12, 24.07% above the 52 week low of 1.71 set on Jul 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.17 |
---|---|
High | 2.21 |
Low | 2.12 |
Bid | 2.12 |
Offer | 2.15 |
Previous close | 2.16 |
Average volume | 129.64k |
---|---|
Shares outstanding | 34.35m |
Free float | 28.33m |
P/E (TTM) | -- |
Market cap | 74.20m USD |
EPS (TTM) | -0.9811 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 18:17 BST.
More ▼